Out of the U.S. No Oversight Necessary?
Today the OIG posted "Challenges to FDA's Ability To Monitor and Inspect Foreign Clinical Trials" (OEI-01-08-00510). As all new investigational drugs and biologics must undergo…
Read More »Today the OIG posted "Challenges to FDA's Ability To Monitor and Inspect Foreign Clinical Trials" (OEI-01-08-00510). As all new investigational drugs and biologics must undergo…
Read More »On April 9th, the FDA issued a Warning Letter to Pfizer, Inc. concerning its conduct during a clinical trial for one of its prescription drugs…
Read More »NEW ORLEANS — Dr. Maria Carmen Palazzo was indicted by a federal grand jury on 55 counts of health care fraud and false documentation in…
Read More »Phase III clinical trials are not necessarily scientifically valid. Misreporting data or its significance is emerging as a reality. Drugs that have become FDA-approved based…
Read More »